This application represents a resubmission of a competing renewal application for a Specialized Program of Research Excellence (SPORE) in Kidney Cancer from the Kidney Cancer Program of Dana-Farber/Harvard Cancer Center (DF/HCC). The DF/HCC Kidney Cancer SPORE has been funded for two cycles since 2003. DF/HCC is comprised of the following institutions: Beth Israel-Deaconess Medical Center (BIDMC); Dana- Farber Cancer Institute (DFCI); Harvard Medical School; Harvard School of Public Health; Brigham and Women?s Hospital; Massachusetts General Hospital (MGH); and Children?s Hospital of Boston. In addition to the institutions in the DF/HCC, the Georgetown-Lombardi Cancer Center (GLCC) is collaborating institutions in this grant. The DF/HCC Kidney Cancer SPORE has its administrative base at the BIDMC. Dr. David McDermott, who has led the DF/HCC Kidney Cancer Program and SPORE since 2012 is joined as SPORE Director by Dr. William Kaelin, a laboratory scientist at DFCI and has served with Dr. McDermott as Director of the SPORE since early 2014. Dr. Kaelin is a world renowned basic and translational investigator with longstanding interest in renal cancer and a leader within the DF/HCC community. Drs. McDermott and Kaelin report directly to Dr. Laurie Glimcher, Director of DF/HCC and President of DFCI. The DF/HCC Kidney Cancer SPORE has a broad and deep talent base and there is extensive institutional commitment. We take advantage of a large patient population and cutting edge technologies that are available to us as part of DF/HCC. We propose 3 Projects which address critical problems in kidney cancer and have translational components. They focus on identifying effective strategies for targeting: HIF2?, the dominant oncogenic driver of clear-cell RCC (Project 1), resistance mechanisms of standard therapies (Projects 2-3, DRP 17), novel immune checkpoint pathways (Project 3) and rare kidney tumor types (e.g. NF2 mutated and translocation RCC, DRP 18 and 17). The projects are supported by three Cores - an Administrative Core, a Biostatistics and Computational Biology Core, and a Tissue Acquisition, Pathology and Clinical Data Core. We also have a highly successful Career Development Program that selects talented physician scientists and mentors them to independence as well as a Developmental Projects Program that generates new ideas for the SPORE in the future. The existence of the SPORE has provided opportunities and incentives to extend basic science and clinical research ideas into the translational realm and facilitated the entry of young, as well as some seasoned, investigators into the kidney cancer field where they have made major contributions.
This SPORE is focused on several important themes in kidney cancer: 1) using the growing understanding of kidney cancer biology to target critical pathways and produce durable clinical benefit for patients with advanced kidney cancer; 2) correlating genomic analyses with clinical outcomes to identify molecular biomarkers for the purposes of monitoring and predicting treatment outcome; 3) understanding the mechanisms by which kidney cancer becomes resistant to standard therapies and developing effective treatment combinations.
|Scelo, Ghislaine; Muller, David C; Riboli, Elio et al. (2018) KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer: A Prospective Nested Case-Control Study. Clin Cancer Res 24:5594-5601|
|Zhang, Jinfang; Bu, Xia; Wang, Haizhen et al. (2018) Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553:91-95|
|Gao, Xin; Jegede, Opeyemi; Gray, Connor et al. (2018) Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clin Genitourin Cancer 16:341-348|
|Liu, Wenjing; Chen, Binbin; Wang, Yang et al. (2018) RGMb protects against acute kidney injury by inhibiting tubular cell necroptosis via an MLKL-dependent mechanism. Proc Natl Acad Sci U S A 115:E1475-E1484|
|Iorgulescu, J Bryan; Braun, David; Oliveira, Giacomo et al. (2018) Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Med 10:87|
|Gopal, Raj K; Kübler, Kirsten; Calvo, Sarah E et al. (2018) Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma. Cancer Cell 34:242-255.e5|
|Nakashima, Hiroshi; Alayo, Quazim A; Penaloza-MacMaster, Pablo et al. (2018) Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 8:208|
|Signoretti, Sabina; Flaifel, Abdallah; Chen, Ying-Bei et al. (2018) Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. J Clin Oncol :JCO2018792259|
|Hamieh, Lana; Choueiri, Toni K; Ogórek, Barbara et al. (2018) Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet 14:e1007679|
|Gao, Xin; McDermott, David F (2018) Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma. Expert Opin Biol Ther 18:947-957|
Showing the most recent 10 out of 153 publications